Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181120 | 0.96 | USP2 (0.53) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3616758 | 0.95 | HPGD (0.53) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21128616 | 0.93 | HPGD (0.55) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27669441 | 0.93 | USP2 (0.56) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31028 | 0.93 | USP2 (0.56) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22859637 | 0.91 | USP2 (0.51) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL23424187 | 0.91 | HPGD (0.55) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL27841683 | 0.91 | USP2 (0.55) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21142469 | 0.90 | HPGD (0.58) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14364845 | 0.90 | HPGD (0.58) | HPGDUSP2SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1059 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152635-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2016-06-02 | — | — | US | claimed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | claimed |
| EP-2400845-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2012-01-04 | — | — | EP | claimed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | claimed |
| EP-4200297-B1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | BIOMEA FUSION, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4100394-B1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-12 | — | — | US | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12552802-B2 | Fused [7,5] bicyclic pyrazole derivatives and methods of use thereof for the treatment of herpesviruses | Merck Sharpe & Dohme LLC (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2000044376-A1 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-6051716-A | ANTIMICROBIAL AGENTS | PHARMACIA & UPJOHN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6043266-A | MICROBIOCIDES TREATING GRAM-POSITIVE BACTERIA INFECTIONS AND PERSONS WITH AIDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| WO-2000000203-A1 | AZEPINE DERIVATIVES HAVING EFFECTS ON SEROTONIN RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| US-5968962-A | ANTIMICROBIAL AGENTS; EFFECTIVE AGAINST GRAMPOSITIVE BACTERIA | PHARMACIA & UPJOHN COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0856002-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997043292-A1 | NEW THIAZOLOPYRIDINES | KLINGE PHARMA GMBH (DE) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997009328-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | HPGD 188/4885USP2 4512/4885SMN1; SMN2 993/4885 |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | GLP1R, GIPR, GPR119 | HPGD 3259/4885USP2 4107/4885SMN1; SMN2 3598/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | HPGD 3680/4885USP2 1960/4885SMN1; SMN2 4318/4885 |
| US-20160152635-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | HPGD 188/4885USP2 4512/4885SMN1; SMN2 993/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | HPGD 2682/4885USP2 1735/4885SMN1; SMN2 3909/4885 |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | CCR3, SCN1B, NR3C1 | HPGD 3292/4885USP2 4159/4885SMN1; SMN2 2639/4885 |
| US-12552802-B2 | Fused [7,5] bicyclic pyrazole derivatives and methods of use thereof for the treatment of herpesviruses | MALT1, CCR1, CCR6 | HPGD 3293/4885USP2 2914/4885SMN1; SMN2 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.